Taxane-induced morphea in a patient with CREST syndrome


Submitted: 29 June 2010
Accepted: 1 July 2010
Published: 20 July 2010
Abstract Views: 1935
PDF: 479
HTML: 1176
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The taxanes, docetaxel and paclitaxel, are microtubule stabilizing chemotherapeutic agents that have demonstrated antineoplastic effects in a variety of solid tumors. They have been linked to the development of localized cutaneous sclerosis in some patients. We present a case of docetaxel-induced cutaneous sclerosis of the lower extremities in a patient with pre-existing CREST syndrome. We propose that patients with a history of limited or diffuse systemic sclerosis should be given taxane chemotherapy with caution, as these patients may have an immunological predisposition for the development of drug-induced morphea.

Susan Michele Bouchard, Eastern Virginia Medical School

Eastern Virginia Medical School, Department of Dermatology

Medical Student

Melinda Mohr, Eastern Virginia Medical School, Department of Dermatology

Eastern Virginia Medical School, Department of Dermatology

PGY3 (Resident Physician)

Robert Pariser, Eastern Virginia Medical School, Department of Dermatology

Eastern Virginia Medical School, Department of Dermatology

Attending Physician

Supporting Agencies


Bouchard, S. M., Mohr, M., & Pariser, R. (2010). Taxane-induced morphea in a patient with CREST syndrome. Dermatology Reports, 2(1), e9. https://doi.org/10.4081/dr.2010.e9

Downloads

Download data is not yet available.

Citations